Hypertension/NN
in/IN
pregnancy/NN
./.

Pregnancy-induced/JJ
hypertension/NN
(/(
PIH/NN
)/)
is/VBZ
a/DT
frequent/JJ
cause/NN
of/IN
maternal/JJ
and/CC
neonatal/JJ
morbidity/NN
and/CC
mortality/NN
./.
=====
In/IN
the/DT
present/JJ
study/NN
we/PRP
focused/VBD
on/IN
the/DT
pathophysiology/NN
of/IN
PIH/NN
,/,
mainly/RB
on/IN
the/DT
role/NN
of/IN
mineralocorticoids/NNS
,/,
reversed/VBN
blood/NN
pressure/NN
patterns/NNS
,/,
and/CC
the/DT
resulting/VBG
necessity/NN
of/IN
continuous/JJ
monitoring/NN
of/IN
the/DT
preeclamptic/JJ
mother/NN
./.
=====
Problems/NNS
of/IN
antihypertensive/JJ
therapy/NN
are/VBP
discussed/VBN
and/CC
the/DT
first/JJ
results/NNS
of/IN
a/DT
pilot/NN
study/NN
with/IN
Urapidil/NN
are/VBP
presented/VBN
./.
=====
To/TO
examine/VB
the/DT
role/NN
of/IN
mineralocorticoids/NNS
in/IN
the/DT
pathophysiology/NN
of/IN
PIH/NN
,/,
we/PRP
studied/VBD
plasma/NN
aldosterone/NN
and/CC
18-hydroxy-corticosterone/NN
(/(
18-OH-B/NN
)/)
levels/NNS
in/IN
25/CD
women/NNS
with/IN
PIH/NN
and/CC
in/IN
25/CD
healthy/JJ
pregnant/JJ
women/NNS
./.
=====
Furthermore/RB
,/,
we/PRP
evaluated/VBD
the/DT
mineralocorticoid/NN
receptor/NN
(/(
MR/NN
)/)
count/NN
in/IN
mononuclear/JJ
leukocytes/NNS
in/IN
the/DT
2/CD
groups/NNS
./.
=====
The/DT
MR-count/NN
was/VBD
significantly/RB
decreased/VBN
in/IN
the/DT
PIH-group/NN
./.
=====
The/DT
values/NNS
of/IN
plasma/NN
aldosterone/NN
and/CC
18-OH-B/NN
were/VBD
also/RB
low/JJ
./.
=====
These/DT
results/NNS
can/MD
not/RB
be/VB
explained/VBN
by/IN
receptor/NN
down-regulation/NN
due/JJ
to/TO
higher/JJR
level/NN
of/IN
mineralocorticoids/NNS
of/IN
the/DT
zona/NN
glomerulosa/NN
./.
=====
Perhaps/RB
deoxycorticosterone/NN
or/CC
a/DT
hitherto/RB
unknown/JJ
mineralocorticoid/NN
is/VBZ
responsible/JJ
for/IN
the/DT
hypertension/NN
and/CC
altered/JJ
MR-status/NN
./.
=====
The/DT
first/JJ
results/NNS
of/IN
continuous/JJ
blood/NN
pressure/NN
measurements/NNS
with/IN
a/DT
noninvasive/JJ
,/,
real-time/JJ
blood/NN
pressure/NN
monitor/NN
(/(
Finapres/NN
)/)
are/VBP
presented/VBN
./.
=====
The/DT
comparison/NN
of/IN
the/DT
obtained/VBN
values/NNS
with/IN
intraarterial/JJ
measurements/NNS
demonstrates/VBZ
a/DT
good/JJ
correlation/NN
between/IN
the/DT
two/CD
methods/NNS
./.
=====
We/PRP
also/RB
report/VBP
on/IN
the/DT
first/JJ
experiences/NNS
with/IN
Urapidil/NN
in/IN
the/DT
treatment/NN
of/IN
hypertension/NN
in/IN
severe/JJ
preeclampsia/NN
./.
=====
The/DT
data/NNS
show/VBP
that/IN
hypertension/NN
in/IN
preeclamptic/JJ
women/NNS
can/MD
be/VB
treated/VBN
by/IN
Urapidil/NN
without/IN
side/JJ
effects/NNS
or/CC
reflex-tachycardia/NN
./.
=====
Further/JJ
studies/NNS
will/MD
have/VB
to/TO
prove/VB
if/IN
Urapidil/NN
is/VBZ
suited/VBN
for/IN
prepartal/JJ
treatment/NN
of/IN
PIH/NN
as/RB
well/RB
./.